Highlights and Quick Summary
- EPS (Basic, from Continuous Ops) for the quarter ending September 30, 2023 was -0.55 (a 17.84% increase compared to previous quarter)
- Year-over-year quarterly EPS (Basic, from Continuous Ops) decreased by -228.87%
- Annual EPS (Basic, from Continuous Ops) for 2022 was -3.59 (a -71.8% decrease from previous year)
- Annual EPS (Basic, from Continuous Ops) for 2021 was -12.75 (a 886.84% increase from previous year)
- Twelve month EPS (Basic, from Continuous Ops) ending September 30, 2023 was -1.03 (a -42.62% decrease compared to previous quarter)
- Twelve month trailing EPS (Basic, from Continuous Ops) decreased by -71.22% year-over-year
Trailing EPS (Basic, from Continuous Ops) for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| -1.03 | -1.8 | -2.79 | -3.59 |
Visit stockrow.com/PRME
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EPS (Basic, from Continuous Ops) of Prime Medicine, Inc.
Most recent EPS (Basic, from Continuous Ops)of PRME including historical data for past 10 years.Interactive Chart of EPS (Basic, from Continuous Ops) of Prime Medicine, Inc.
Prime Medicine, Inc. EPS (Basic, from Continuous Ops) for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | -0.55 | -0.47 | -0.44 | – | – |
| 2022 | 0.43 | -1.32 | -1.45 | -1.25 | -3.59 |
| 2021 | – | – | – | -1.1 | -12.75 |
| 2020 | – | – | – | – | -1.29 |
Business Profile of Prime Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology